[go: up one dir, main page]

MXPA03004341A - Nuevo uso de combinaciones de agonsitas de 5-ht1a e inhibidores selectivos de la recaptacion de serotonina. - Google Patents

Nuevo uso de combinaciones de agonsitas de 5-ht1a e inhibidores selectivos de la recaptacion de serotonina.

Info

Publication number
MXPA03004341A
MXPA03004341A MXPA03004341A MXPA03004341A MXPA03004341A MX PA03004341 A MXPA03004341 A MX PA03004341A MX PA03004341 A MXPA03004341 A MX PA03004341A MX PA03004341 A MXPA03004341 A MX PA03004341A MX PA03004341 A MXPA03004341 A MX PA03004341A
Authority
MX
Mexico
Prior art keywords
ht1a
combined
novel use
novel
Prior art date
Application number
MXPA03004341A
Other languages
English (en)
Inventor
Gerd Bartoszyk
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MXPA03004341A publication Critical patent/MXPA03004341A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
MXPA03004341A 2000-11-20 2001-11-02 Nuevo uso de combinaciones de agonsitas de 5-ht1a e inhibidores selectivos de la recaptacion de serotonina. MXPA03004341A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00125409 2000-11-20
PCT/EP2001/012686 WO2002039989A1 (en) 2000-11-20 2001-11-02 Novel use of combined 5-ht1a agonists and selective serotonin reuptake inhibitors

Publications (1)

Publication Number Publication Date
MXPA03004341A true MXPA03004341A (es) 2003-08-19

Family

ID=8170432

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03004341A MXPA03004341A (es) 2000-11-20 2001-11-02 Nuevo uso de combinaciones de agonsitas de 5-ht1a e inhibidores selectivos de la recaptacion de serotonina.

Country Status (19)

Country Link
US (1) US7479492B2 (es)
EP (1) EP1335716A1 (es)
JP (1) JP2004513916A (es)
KR (1) KR20030048477A (es)
CN (1) CN1541093A (es)
AR (1) AR031463A1 (es)
AU (2) AU2180302A (es)
BR (1) BR0115434A (es)
CA (1) CA2429216C (es)
CZ (1) CZ20031448A3 (es)
HU (1) HUP0400504A3 (es)
MX (1) MXPA03004341A (es)
NO (1) NO20032248L (es)
PL (1) PL361617A1 (es)
RU (1) RU2302243C2 (es)
SK (1) SK6442003A3 (es)
UA (1) UA76130C2 (es)
WO (1) WO2002039989A1 (es)
ZA (1) ZA200304757B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10326939A1 (de) * 2003-06-16 2005-01-05 Merck Patent Gmbh Indol-Derivate
EP1732610A2 (en) 2004-03-26 2006-12-20 Baylor University Targeted serotonin reuptake inhibitors
US20080318931A1 (en) * 2004-07-08 2008-12-25 Moshe Arkin Treatment of Disorders and Diseases of the Colon
WO2007007910A1 (ja) 2005-07-13 2007-01-18 Banyu Pharmaceutical Co., Ltd. ヘテロ環置換ベンズイミダゾール誘導体
ZA200810017B (en) 2006-06-16 2010-04-28 Lundbeck & Co As H 1- [2- (2, 4-Dimethylphenylsulfanyl) -phenyl] piperazine as a compound with combined serotonin Reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
TW200848411A (en) * 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
RU2412714C1 (ru) * 2009-08-05 2011-02-27 Михаил Владимирович Покровский Способ моделирования эндотелиальной дисфункции путем воспроизведения метаболических нарушений

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2222768B (en) 1988-06-17 1992-01-22 Nat Res Dev Analgesic compounds and compositions
US5589511A (en) * 1990-08-13 1996-12-31 Sepracor Inc. Method for treating migraine headaches using optically pure S(+) fluoxetine
US5578612A (en) * 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
US5434174A (en) 1992-07-17 1995-07-18 Eli Lilly And Company Isoxazole derivatives for the treatment of irritable bowel syndrome
DE4333254A1 (de) * 1993-09-30 1995-04-06 Merck Patent Gmbh Piperidine und Piperazine
US5576321A (en) * 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
DE19512639A1 (de) 1995-04-05 1996-10-10 Merck Patent Gmbh Benzonitrile und -fluoride
US5912256A (en) 1996-06-20 1999-06-15 Eli Lilly And Company Compounds having effects on serotonin-related systems
UA56185C2 (uk) * 1996-09-30 2003-05-15 Пфайзер Інк. Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування
GB9911863D0 (en) * 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
TW518218B (en) 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders

Also Published As

Publication number Publication date
EP1335716A1 (en) 2003-08-20
CA2429216A1 (en) 2002-05-23
BR0115434A (pt) 2003-10-07
SK6442003A3 (en) 2003-09-11
AU2180302A (en) 2002-05-27
NO20032248D0 (no) 2003-05-19
KR20030048477A (ko) 2003-06-19
US7479492B2 (en) 2009-01-20
UA76130C2 (en) 2006-07-17
ZA200304757B (en) 2004-09-20
HUP0400504A2 (hu) 2004-06-28
HUP0400504A3 (en) 2006-02-28
US20040014771A1 (en) 2004-01-22
NO20032248L (no) 2003-05-19
CN1541093A (zh) 2004-10-27
AR031463A1 (es) 2003-09-24
RU2302243C2 (ru) 2007-07-10
WO2002039989A1 (en) 2002-05-23
CZ20031448A3 (cs) 2003-09-17
AU2002221803B2 (en) 2007-02-15
JP2004513916A (ja) 2004-05-13
PL361617A1 (en) 2004-10-04
CA2429216C (en) 2012-08-07

Similar Documents

Publication Publication Date Title
ZA200204020B (en) Use of anti-CTLA-4-antibodies.
PL357210A1 (en) Novel use
IL162266A (en) Substituted 2-thio-3,5-dicyano-4- phenyl-6-aminopyridines and the use of the same
ZA200404306B (en) 3'-prodrugs of 2'-deoxy-beta-L-nucleosides.
ZA200205479B (en) Novel biarylcarboxamides.
ZA200206198B (en) New aza-indolyl derivatives.
MXPA03007093A (es) Nueva composicion.
MXPA03007834A (es) Uso de agonistas inversos de gabaa, en combinacion con agonistas parciales del receptor de nicotina, estrogenos, moduladores selectivos de estrogenos o vitamina e, para el tratamiento de transtornos cognitivos.
EG23361A (en) High utility tissue.
ZA200307102B (en) The use of enmantiomeric pure escitalopram.
MXPA03006603A (es) Agonista de subtipo de receptor 5-ht1a.
MXPA03007314A (es) Composicion para la piel para reducir aceites y grasa de la piel.
MXPA03001991A (es) Novedosas arilalcano-sulfonamidas.
MXPA03000914A (es) Sintesis de (r)-3-(4 -bromobencil) -1-(3, 5-diclorofenil) -5-yodo-3 -metil-1-h -imidazo[1, 2-a]imidazol -2-ona.
MXPA03004166A (es) Nuevos usos de combinaciones de agonistas de 5-ht1a e inhibidores de la recaptacion de serotonina.
MXPA03004341A (es) Nuevo uso de combinaciones de agonsitas de 5-ht1a e inhibidores selectivos de la recaptacion de serotonina.
ZA200205168B (en) Synthesis and use of dimethyl-1,5-naphthalenedicarboxylates and intermediates therefrom.
MXPA03007888A (es) Compuestos para tratamiento y prevencion de ulcera gastrica inducida por medicamentos.
ZA200109120B (en) Use of Arylalkanoylpyridazines.
GB0027783D0 (en) Novel use
MXPA03006970A (es) Nuevo uso de iloperidona.
AU2002219846A1 (en) Novel use
GB0019524D0 (en) Novel use
ZA200306611B (en) New use.
AU2002331285A1 (en) Use of 1,1,1,3,3-pentafluorobutan

Legal Events

Date Code Title Description
FG Grant or registration
GD Licence granted
GD Licence granted